Abstract:Reduced inhibition by somatostatin-expressing interneurons is associated with depression. Administration of positive allosteric modulators of α5 subunit-containing GABA A receptor (α5-PAM) that selectively target this lost inhibition exhibit antidepressant and pro-cognitive effects in rodent models of chronic stress. However, the functional effects of α5-PAM on the human brain in vivo are unknown, and currently cannot be assessed experimentally. We modeled the effects of α5-PAM on tonic inhibition as measured in human neurons, and tested in silico α5-PAM effects on detailed models of human cortical microcircuits in health and depression. We found that α5-PAM effectively recovered impaired cortical processing as quantified by stimulus detection metrics, and also recovered the power spectral density profile of the microcircuit EEG signals. We performed an α5-PAM dose-response and identified simulated EEG biomarker candidates. Our results serve to de-risk and facilitate α5-PAM translation and provide biomarkers in non-invasive brain signals for monitoring target engagement and drug efficacy.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the potential efficacy of positive allosteric modulators of the α5 - subunit GABA A receptor (α5 - PAM) in restoring the inhibitory function of the cerebral cortex in patients with depression. Specifically, the study aims to evaluate the impact of α5 - PAM on the human cortical micro - circuit by computer simulation methods, especially how to restore normal neural activity and cognitive function in a depressed state. ### Research Background and Problems 1. **The Relationship between Depression and Inhibitory Neurons** - Depression is related to the decreased activity of inhibitory interneurons expressing somatostatin (SST) in the cerebral cortex. These neurons usually provide synaptic and tonic inhibition through the α5 - subunit GABA A receptor. - The weakened inhibitory function caused by the reduction of SST interneurons is considered an important pathological mechanism of depression. 2. **The Mechanism of Action of α5 - PAM** - α5 - PAM is a compound that selectively enhances the activity of the α5 - subunit GABA A receptor and has shown antidepressant and pro - cognitive effects in rodent models. - However, the specific impact of α5 - PAM on the human brain is still unclear because there are ethical and technical limitations in direct experiments. 3. **Research Objectives** - Evaluate the potential efficacy of α5 - PAM on the human cortical micro - circuit through computer simulation, especially its impact on indicators such as signal detection and EEG power spectral density. - Determine the optimal dose range of α5 - PAM and identify non - invasive electroencephalogram (EEG) biomarkers that can be used to monitor the drug effect. ### Main Research Contents - **Experimental Verification**: First, the effect of α5 - PAM on the tonic inhibitory current was recorded in a single human cortical pyramidal neuron, and it was found that α5 - PAM significantly enhanced this current. - **Model Construction**: Based on the experimental data, a detailed L2/3 cortical micro - circuit model was constructed, including models in healthy and depressed states. - **Simulation Testing**: Different doses of α5 - PAM were applied in the simulated depressed micro - circuit to evaluate its recovery effect on indicators such as the baseline firing rate, signal detection error rate, and EEG power spectral density. - **Dose - Response Relationship**: The dose - response relationship of different doses of α5 - PAM on the micro - circuit function was analyzed to determine the optimal dose. - **EEG Biomarkers**: By simulating EEG signals, the power changes of α5 - PAM in different frequency bands (such as theta, alpha, beta) were identified as potential biomarkers. ### Conclusions The study shows that α5 - PAM can effectively restore the damaged cortical processing function in a depressed state, especially in terms of stimulus detection and EEG signal characteristics. These findings provide important theoretical support for the application of α5 - PAM in the clinical treatment of depression and propose non - invasive EEG biomarkers that may be used to monitor drug efficacy.

In-silico testing of new pharmacology for restoring inhibition and human cortical function in depression

Therapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

In-silico EEG biomarkers of reduced inhibition in human cortical microcircuits in depression

EEG biomarkers of α5-GABA positive allosteric modulators in rodents

Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions

Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit–Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice

In silico Screening of Monamine Oxidase B Inhibitors for the Treatment of Central Nervous System Disorders

Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits

Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors

Validation of a functional human AD model with four AD therapeutics utilizing patterned ipsc-derived cortical neurons integrated with microelectrode arrays

Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel Mglu5 Positive Allosteric Modulator.

Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation

NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice

Reversible and Noninvasive Modulation of a Historical Surgical Target for Depression with Low Intensity Focused Ultrasound

Scopolamine provocation-based pharmacological MRI model for testing procognitive agents

Intra-Prefrontal S-Oh-Dpat And M100907 Improve Visuospatial Attention And Decrease Impulsivity On The Five-Choice Serial Reaction Time Task In Rats

Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders

A Multiple-step Screening Protocol to Identify Norepinephrine and Dopamine Reuptake Inhibitors for Depression